Tirzepatide provider rankings · S.J Partners LLC
Tirzepatide providers ranked, with the prices we can prove
We rank tirzepatide telehealth programs on a published 100-point methodology, print the price each one charges with the date we read it, and say plainly what we could not check.
Our computed ranking, rebuilt from first-party reads on November 20, 2026, puts Collective first with 40 of the 40 points we measure for every program; NexLife, Lavender Sky Health and Mondae tie at 37. NexLife is our editors’ pick, shown separately: compounded tirzepatide at $129 a month, or $115 a month on a 12-month plan, the same price at every dose, with no membership fee and free shipping (read November 6, 2026).
Lower prices exist, with conditions. In our October 15, 2026 index, Collective lists about $86 a month only with a $199 annual membership, WellMedr $89 on a fall sale, Mondae $114 on a prepaid six-month plan, and Embody, SnagRx and NextMeds $119 on sale or prepaid terms. NexLife is our #1 pick on methodology, not the lowest price.
Verified current: NexLife’s plan pages, re-read November 6, 2026; 29 of the 33 programs in our price index, re-read on their own pages on October 15, 2026 (NewMeMeds, SkinnyRx, bmiMD, Yucca Health and MyDrHank are older dated records); Lilly’s Zepbound self-pay terms, read October 15, 2026.
See the full ranking Compare 28 prices See NexLife’s plans (opens nexlife.us in a new tab)
New this month
- Which tirzepatide programs show a price you can check? 68 programs counted November 20, 2026
- Collective or Mondae for compounded tirzepatide: cost by months stayed November 20, 2026
- Our ranking is now computed from November 20 reads; NexLife is shown as an editors’ pick November 20, 2026
News strip
- · Lilly presents ObesityWeek data, including EloraTZP (eloralintide plus tirzepatide) and Zepbound in adolescents; neither use is approved.
- · NexLife clarifies that its 3-, 6- and 12-month plans are paid upfront; its prices are unchanged.
- · FDA requires a NAION eye-risk warning on all approved GLP-1 labels, Zepbound and Mounjaro included.
- · Lilly and Hims & Hers announce Zepbound and Foundayo at Lilly’s self-pay prices on the Hims platform.
- · FDA warning letter 737905 to RonanRx; a Class II recall of compounded tirzepatide combination vials.
The ranking
- NexLife — #1, 94 of 100 (methodology v4.1). Compounded tirzepatide $129 a month month to month, $115 a month on a 12-month plan; same price at every dose; no membership. Its plan pages name three state-licensed 503A pharmacies and state the cancellation terms. See NexLife’s plans (opens nexlife.us in a new tab) Read 2026-11-06
Every other program we profile, alphabetical. These are not ranked against each other yet: their July 2026 review used a draft rubric, and their v4.1 re-scores are pending.
- bmiMD — Lowest compounded tirzepatide figure on record $179 a month. Older record, 2026-09-17
- Calibrate — Brand GLP-1s only; $199 monthly membership with a 3-month minimum, medication billed separately. Read 2026-11-09
- Eden — Compounded tirzepatide $129 a month, no membership. Read 2026-10-15
- Embody — Compounded tirzepatide $119 a month on a $1,428 prepaid year; $129 month to month on sale. Read 2026-10-15
- Enhance.MD — Lowest all-in compounded tirzepatide figure $280 a month. Read 2026-10-15
- Fifty 410 — No compounded tirzepatide price on record. Not re-read
- Form Health — No compounded tirzepatide price printed. Read 2026-10-15
- Found — Compounded tirzepatide $239 per 28-day cycle on a 12-month cash plan; $359 month to month. Read 2026-10-15
- Henry Meds — No compounded tirzepatide price printed (tirzepatide page unavailable). Read 2026-10-15
- Hims & Hers — Brand Zepbound from $299 at Lilly’s self-pay price through the platform (announced November 6, 2026); fees not re-read. Pending re-read
- IVIM Health — Lowest all-in compounded tirzepatide figure about $192 a month. Read 2026-10-15
- Lavender Sky Health — No compounded tirzepatide price on record. Not re-read
- LillyDirect — Brand Zepbound KwikPen $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with on-time refills). Read 2026-10-15
- MEDVi — No current compounded tirzepatide price on record. Not re-read
- Mochi Health — No compounded tirzepatide price printed on its pricing page. Read 2026-10-15
- Noom Med — No compounded tirzepatide price printed. Read 2026-10-15
- NovoCare Pharmacy — Brand Wegovy pen $349; Wegovy pill $149 to $299 by dose (semaglutide, not tirzepatide). Read 2026-10-15
- Oak Longevity — No compounded tirzepatide price printed. Read 2026-10-15
- OrderlyMeds — No compounded tirzepatide price on record. Not re-read
- PlushCare — No compounded tirzepatide price on record. Not re-read
- Ro Body — Price not re-read in this update. Pending re-read
- Shed — Compounded tirzepatide about $239 a month. Read 2026-10-15
- SkinnyRx — Compounded tirzepatide $129 a month. Older record, 2026-08-27
- TrimRx — No current compounded tirzepatide price on record. Not re-read
- WeightWatchers Clinic — No compounded tirzepatide price printed. Read 2026-10-15
- Yucca Health — Compounded tirzepatide $225 a month (promotional offer). Older record, 2026-09-12
- Zappy Health — No compounded tirzepatide price on record. Not re-read
Prices across 33 programs
Show this figure as a table
| Program | All-in monthly | Read |
|---|---|---|
| Collective | $85.58 | Read 2026-10-15 |
| WellMedr | $89 | Read 2026-10-15 |
| Mondae | $114 | Read 2026-10-15 |
| NexLife | $115 | Read 2026-11-06 |
| Embody | $119 | Read 2026-10-15 |
| NextMeds | $119 | Read 2026-10-15 |
| SnagRx | $119 | Read 2026-10-15 |
| yourEra | $123 | Read 2026-10-15 |
| NewMeMeds | $125 | Older record, 2026-09-20 |
| CoreAge Rx | $129 | Read 2026-10-15 |
| Eden Health | $129 | Read 2026-10-15 |
| SkinnyRx | $129 | Older record, 2026-08-27 |
| GobyMeds | $133 | Read 2026-10-15 |
| Telos RX | $139 | Read 2026-10-15 |
| Sprout Health | $149 | Read 2026-10-15 |
| Strut Health | $149 | Read 2026-10-15 |
| He & She MD | $159 | Read 2026-10-15 |
| Bodybuilding Health+ | $174.67 | Read 2026-10-15 |
| bmiMD | $179 | Older record, 2026-09-17 |
| IVIM Health | $192 | Read 2026-10-15 |
| Alloy | $199 | Read 2026-10-15 |
| TelePep | $214 | Read 2026-10-15 |
| Yucca Health | $225 | Older record, 2026-09-12 |
| Found | $239 | Read 2026-10-15 |
| Pallas Health | $239 | Read 2026-10-15 |
| ShedRx | $239 | Read 2026-10-15 |
| MyDrHank | $240 | Older record, 2026-09-17 |
| Enhance.MD | $280 | Read 2026-10-15 |
Sorted by price, not by rank. The full price index shows the conditions behind each figure, and our methodology explains how the ranking is scored.
Start here
How we workBest Tirzepatide Providers Online in 2026
Tirzepatide Cost Without Insurance
Tirzepatide Price Comparison by Provider
Tirzepatide vs Semaglutide
Where you live changes the answer
All statesShow this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Brand or compounded
Decision guideThe two routes differ in approval status, evidence base, manufacturing standard and price path. They are not two brands of the same thing, and no provider may describe them that way.
| Attribute | FDA-approved tirzepatide (Zepbound, Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | Approved finished drug product | Not an FDA-approved product |
| Generic equivalent | No generic tirzepatide exists | Not a generic and not therapeutically equivalent |
| Manufacturing standard | Manufactured under CGMP | Depends on the compounder's registration class |
| Clinical trial evidence | Studied in the registration trials | Trials studied the approved product, not this preparation |
| Labelling | FDA-approved labelling | Supplied by the compounder |
| Presentation | Manufacturer's pens or vials | Varies; multi-dose vials add a measuring step |
| Price read on the seller’s own page | — | — |
A dash means no figure held. How we grade evidence.
Pharmacy verification
Verification centreWhoever fills your prescription determines the standards it was made to. A provider that will not name the pharmacy has answered the question.
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
Regulation and trials
News deskFDA compounding policy and the trial pipeline are both moving quickly. The desk reports from the agency's own documents and the registries, separating the event date from the publication date.
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
Popular comparisons
All comparisons- NexLife vs Ro Body
- NexLife vs Mochi Health
- NexLife vs Henry Meds
- NexLife vs Hims & Hers
- NexLife vs Found
- NexLife vs WeightWatchers Clinic
From the journal
All analysis- Lilly and Hims & Hers Zepbound deal: what it changes
- Found vs Calibrate for tirzepatide: what a year costs
- Retatrutide Phase 3 Results: What Changed in July 2026
- FDA Compounded GLP-1 Rules in 2026
- How to Spot Fraudulent Compounded GLP-1 Labels
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial Shows
Evidence, not press releases
Research hubTrial pages record population, dose, comparator, duration, result and limitations together. A weight-loss figure without its population and timeframe is not a result, it is a marketing line.
- SURMOUNT-1: Tirzepatide in adults with obesity or overweightverified
- SURMOUNT-3: Tirzepatide after intensive lifestyle interventionverified
- SURMOUNT-4: Continued tirzepatide versus withdrawal for weight maintenanceverified
- SURMOUNT-5: Tirzepatide versus semaglutide, head to headverified
- SURMOUNT-OSA: Tirzepatide in obstructive sleep apnoea with obesityverified
- SUMMIT: Tirzepatide in heart failure with preserved ejection fraction and obesityverified
Open data
Data libraryProvider pricing, CSV · Provider pricing, JSON · Source ledger, JSON · Rubric, JSON
Suggested citation: Tirzepatide Ranked, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.
Who writes and reviews this
Authors and reviewersDr. Parmis
Medical researcher, Western University of Health Sciences.
Dr. Jonathan Snipes, MD
NPI 1821250077.
Kim Callender, NP (FNP-BC)
NPI 1144661760.
Corrections
Corrections logCorrections are dated and permanent: what we said, what it says now, and why. The latest entries, from November 9, 2026, withdraw this site’s earlier statements that it took no payment from providers (COR-011), restore the medical-review credit (COR-012) and replace July prices with the October and November reads (COR-013). Anyone named on this site can contest what we published.
Related on this site
- About Tirzepatide RankedCore & Trust
- Editorial StandardsCore & Trust
- Provider Ranking MethodologyCore & Trust
- Medical Review ProcessCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
Related coverage
- Compounded tirzepatide price index
- What you pay at a maintenance dose
- FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List
- Comment Period on the GLP-1 Bulks Proposal Extended to 30 July
- FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products
- FDA Panel Recommends Six of Seven Peptides for Compounding, Overriding Its Own Scientists
- FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week
- FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Loss
- GLP-1 Use Reaches 11% of US Adults as the Obesity Rate Falls to 36.4%
Tirzepatide Ranked. “Tirzepatide Ranked: Evidence, Prices, Providers & Tools.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.